866-997-4948(US-Canada Toll Free)

Gastritis - Pipeline Review, H2 2017

Published By :

Global Markets Direct

Published Date : Nov 2017

Category :

Pharmaceutical

No. of Pages : 51 Pages

Gastritis - Pipeline Review, H2 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Gastritis - Pipeline Review, H2 2017, provides an overview of the Gastritis (Gastrointestinal) pipeline landscape.

Gastritis is characterized by inflammation or swelling of the lining of the stomach. Acute gastritis lasts for a short period of time while chronic gastritis lasts for a long period of time (months to years). Gastritis can be caused by medications such as ibuprofen, aspirin, naproxen on long periods of consumption, excess intake of alcohol, Helicobacter pylori infection, certain autoimmune disorders, bile reflux, substance abuse (cocaine), consumption of corrosive or caustic substances such as poisons, extreme stress, viral infections and trauma. The symptoms of gastritis may include loss of appetite, nausea and vomiting, abdominal pain and black stools. Treatment includes use of antacids, Histamine 2 (H2) antagonists and proton pump inhibitors.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Gastritis - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Gastritis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Gastritis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Gastritis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 3, 3 and 2 respectively.

Gastritis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Gastritis (Gastrointestinal).
- The pipeline guide reviews pipeline therapeutics for Gastritis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Gastritis (Gastrointestinal) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Gastritis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Gastritis (Gastrointestinal)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Gastritis (Gastrointestinal).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Gastritis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Gastritis - Overview 6
Gastritis - Therapeutics Development 7
Pipeline Overview 7
Pipeline by Companies 8
Products under Development by Companies 9
Gastritis - Therapeutics Assessment 10
Assessment by Target 10
Assessment by Mechanism of Action 12
Assessment by Route of Administration 14
Assessment by Molecule Type 16
Gastritis - Companies Involved in Therapeutics Development 17
BCWorld Pharm Co Ltd 17
Boryung Pharmaceutical Co Ltd 17
Daewon Pharm Co Ltd 18
Daewoong Pharmaceutical Co Ltd 18
Recce Ltd 19
RedHill Biopharma Ltd 19
Sequella Inc 19
Gastritis - Drug Profiles 21
BCWPA-001 - Drug Profile 21
Product Description 21
Mechanism Of Action 21
R&D Progress 21
BGC-001 - Drug Profile 22
Product Description 22
Mechanism Of Action 22
R&D Progress 22
DW-3101 - Drug Profile 23
Product Description 23
Mechanism Of Action 23
R&D Progress 23
DWJ-1366 - Drug Profile 24
Product Description 24
Mechanism Of Action 24
R&D Progress 24
HPi-1 - Drug Profile 25
Product Description 25
Mechanism Of Action 25
R&D Progress 25
netazepide - Drug Profile 26
Product Description 26
Mechanism Of Action 26
R&D Progress 26
ondansetron hydrochloride CR - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
RECCE-327 - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
SQ-109 - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
Gastritis - Dormant Projects 43
Gastritis - Product Development Milestones 44
Featured News & Press Releases 44
Jun 19, 2017: RedHill Biopharma to Host Conference Call on Successful Phase III Top-Line Results with BEKINDA for Acute Gastroenteritis 44
Feb 13, 2017: RedHill Biopharma Announces Enrollment of Last Patient in BEKINDA Phase III Study for Acute Gastroenteritis 44
Nov 03, 2016: RedHill Biopharma Provides Update on Ongoing Phase III and Phase II studies with BEKINDA and Expected Timing of Top-Line Results 45
Mar 02, 2015: Positive Bioavailability Studies of RedHill's BEKINDA to be Presented at the 2015 American Society for Clinical Pharmacology and Therapeutics Meeting 46
Dec 17, 2014: RedHill Biopharma Announces First Patients Enrolled in the Phase III Study of RHB-102 (BEKINDA) for Gastroenteritis and Gastritis 47
Dec 09, 2014: RedHill Biopharma Submits BEKINDA (RHB-102) European Marketing Authorization Application for Oncology Support 48
Appendix 50
Methodology 50
Coverage 50
Secondary Research 50
Primary Research 50
Expert Panel Validation 50
Contact Us 50
Disclaimer 51

List of Tables
Number of Products under Development for Gastritis, H2 2017 7
Number of Products under Development by Companies, H2 2017 8
Products under Development by Companies, H2 2017 9
Number of Products by Stage and Target, H2 2017 11
Number of Products by Stage and Mechanism of Action, H2 2017 13
Number of Products by Stage and Route of Administration, H2 2017 15
Number of Products by Stage and Molecule Type, H2 2017 16
Gastritis - Pipeline by BCWorld Pharm Co Ltd, H2 2017 17
Gastritis - Pipeline by Boryung Pharmaceutical Co Ltd, H2 2017 17
Gastritis - Pipeline by Daewon Pharm Co Ltd, H2 2017 18
Gastritis - Pipeline by Daewoong Pharmaceutical Co Ltd, H2 2017 18
Gastritis - Pipeline by Recce Ltd, H2 2017 19
Gastritis - Pipeline by RedHill Biopharma Ltd, H2 2017 19
Gastritis - Pipeline by Sequella Inc, H2 2017 20
Gastritis - Dormant Projects, H2 2017 43

List of Figures
Number of Products under Development for Gastritis, H2 2017 7
Number of Products under Development by Companies, H2 2017 8
Number of Products by Targets, H2 2017 10
Number of Products by Stage and Targets, H2 2017 10
Number of Products by Mechanism of Actions, H2 2017 12
Number of Products by Stage and Mechanism of Actions, H2 2017 12
Number of Products by Routes of Administration, H2 2017 14
Number of Products by Stage and Routes of Administration, H2 2017 14
Number of Products by Stage and Molecule Types, H2 2017 16

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *